Merck, Inc.
🇺🇸United States
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)
Phase 3
Completed
- Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 68
- Registration Number
- NCT01824238
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Terminated
- Conditions
- Human Immunodeficiency Virus
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT01814722
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 203
- Registration Number
- NCT01814748
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01813513
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
Phase 1
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01813552
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 135
- Registration Number
- NCT01803607
A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo for MK-8892
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01798849
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01797536
- Locations
- 🇺🇸
Call for Information (Investigational Site 0001), Orlando, Florida, United States
🇺🇸Call for Information (Investigational Site 0003), Miami, Florida, United States
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
Phase 3
Completed
- Conditions
- Fungal InfectionsInvasive Pulmonary Aspergillosis
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 585
- Registration Number
- NCT01782131
Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
Phase 1
Completed
- Conditions
- Fungal Infections
- Interventions
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT01777763